Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
- 1 January 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 22 (1), 74-84
- https://doi.org/10.1016/s1470-2045(20)30534-9
Abstract
No abstract availableKeywords
Funding Information
- Taiho Pharmaceutical
This publication has 24 references indexed in Scilit:
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 StatusJNCI Journal of the National Cancer Institute, 2014
- 1st International consensus guidelines for advanced breast cancer (ABC 1)The Breast, 2012
- Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patientsCancer Science, 2010
- Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial)Breast Cancer Research and Treatment, 2009
- Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative studyBritish Journal of Cancer, 2009
- Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 TrialJournal of Clinical Oncology, 2009
- Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical TrialsJournal of Clinical Oncology, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineThe New England Journal of Medicine, 2007
- Comparison of the Efficacy, Toxicity, and Pharmacokinetics of a Uracil/Tegafur (UFT) Plus Oral Leucovorin (LV) Regimen Between Japanese and American Patients With Advanced Colorectal Cancer: Joint United States and Japan Study of UFT/LVJournal of Clinical Oncology, 2004
- Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the nishinihon cooperative study group of adjuvant chemoendocrine therapy for breast cancer (ACETBC) of JapanEuropean Journal of Cancer, 1996